Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Dettagli
Tipi di conto
CFD Trading: MetaTrader 5
CFD Trading: MetaTrader 5
Investing: Web
Commissione
0.1%
Sessione trading (UTC)
Aperta oraChiusa oraChiudeApre
alle
-
Gli orari di apertura sono indicati nel tuo fuso orario locale
(UTC)
Apri un conto e investi subito con Metadoro. Invita gli amici e verrai ricompensato per la loro operatività. Troverai maggiori informazioni sul programma di affiliazione nella tua area personale.
Grazie per la visita metadoro.com. Questo sito Web è gestito da RHC Investments, che è autorizzata e regolamentata come rivenditore di investimenti dalla Financial Services Commission di Mauritius con numero di licenza C115015381. Mauritius non fa parte del quadro normativo europeo e non rientra nell'ambito di applicazione (tra gli altri) della Direttiva sui mercati degli strumenti finanziari (MiFID) II.
Continuando confermi che la decisione è presa in modo indipendente e di tua esclusiva iniziativa e che nessuna sollecitazione o raccomandazione è stata fatta da RHC Investments.
Personalizza l'abbonamento a modo tuo!Create a Newsletter
Customize your subscriptions the way you want!
Analytics
Get notified upon new posts
Select category
Price alerts
Rilevamento tempestivo di alti e bassi del mercato, fluttuazioni, ecc.
Select category
Alert method
All categoriescategoriesAll instrumentsinstrumentssearchNothing found